A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis

This multicenter, randomized, open-label clinical trial aims to evaluate the efficacy and safety of taurine as an adjunctive therapy to standard disease-modifying treatments (DMTs) in patients with multiple sclerosis (MS). The study seeks to determine whether oral taurine can reduce the number and volume of new or enlarging MRI lesions, decrease relapse rates, and slow disability progression as measured by the Expanded Disability Status Scale (EDSS). It will also explore the effects of taurine on gut microbiota composition, serum neurodegeneration biomarkers (GFAP and NfL), and cognitive function assessed by MMSE and MoCA. Approximately 80 eligible participants will be enrolled and randomly assigned to either continue standard DMT therapy or receive taurine supplementation in addition to DMTs. The treatment duration will be 24 months, with follow-up visits every 3 months for clinical assessment, blood and stool sample collection, and MRI scans every 6 months. This study aims to provide new clinical evidence supporting taurine as a safe and potentially beneficial adjunctive therapy for multiple sclerosis.

NCT Number	NCT07263607
Lead Sponsor	Sichuan Academy of Medical Sciences Collaborators: First Affiliated Hospital of Chongqing Medical University, Tang-Du Hospital, The First Affiliated Hospital of Hainan Medical University, Lanzhou University Second Hospital, First Affiliated Hospital of Kunming Medical University, Daping Hospital of Army Medical University, Shandong Provincial Hospital, Affiliated Hospital of North Sichuan Medical College, Beijing Tiantan Hospital, The People's Hospital of Leshan, The Affiliated Hospital of Inner Mongolia Medical University
Conditions	Multiple Sclerosis (MS) Relapsing Remitting
Enrollment	80 participants
Start Date	2026-01-01
Primary Completion	2029-07 (estimated)
Study Completion	2029-11 (estimated)
Updated on ClinicalTrials.gov	2025-12-04